Wuhan Keqian Biology to Enter Joint R&D Agreement with Huazhong Agricultural University

Stock News03-24

Wuhan Keqian Biology Co.,Ltd. (688526.SH) has announced plans to sign a joint research and development agreement with Huazhong Agricultural University. The collaboration aims to enhance the company's market competitiveness and accelerate its growth within the biological products sector, thereby strengthening its brand influence and core capabilities.

Following a competitive negotiation process, the company has secured the joint R&D project for a "Feline Quadrivalent Inactivated Vaccine (against feline panleukopenia virus, calicivirus, herpesvirus, and mycoplasma) and a Feline Mycoplasma Inactivated Vaccine." Under the agreement, the company will pay Huazhong Agricultural University RMB 1 million for the research initiative.

This partnership is expected to expand the company's product pipeline and improve its competitive position in the market. However, as the project involves early-stage R&D, there are uncertainties regarding successful product development, time to market, and post-launch commercial performance. The impact of the project on the company's current and future financial results cannot be reliably estimated at this stage.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1176014928?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-24 17:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1176014928","market":"hk","top_or_hot":-1,"title":"Wuhan Keqian Biology to Enter Joint R&D Agreement with Huazhong Agricultural University","media":"Stock News","content":"<p>Wuhan Keqian Biology Co.,Ltd. (688526.SH) has announced plans to sign a joint research and development agreement with Huazhong Agricultural University. The collaboration aims to enhance the company's market competitiveness and accelerate its growth within the biological products sector, thereby strengthening its brand influence and core capabilities.</p>\n<p>Following a competitive negotiation process, the company has secured the joint R&D project for a \"Feline Quadrivalent Inactivated Vaccine (against feline panleukopenia virus, calicivirus, herpesvirus, and mycoplasma) and a Feline Mycoplasma Inactivated Vaccine.\" Under the agreement, the company will pay Huazhong Agricultural University RMB 1 million for the research initiative.</p>\n<p>This partnership is expected to expand the company's product pipeline and improve its competitive position in the market. However, as the project involves early-stage R&D, there are uncertainties regarding successful product development, time to market, and post-launch commercial performance. The impact of the project on the company's current and future financial results cannot be reliably estimated at this stage.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Wuhan Keqian Biology to Enter Joint R&D Agreement with Huazhong Agricultural University</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWuhan Keqian Biology to Enter Joint R&D Agreement with Huazhong Agricultural University\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-03-24 17:18</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Wuhan Keqian Biology Co.,Ltd. (688526.SH) has announced plans to sign a joint research and development agreement with Huazhong Agricultural University. The collaboration aims to enhance the company's market competitiveness and accelerate its growth within the biological products sector, thereby strengthening its brand influence and core capabilities.</p>\n<p>Following a competitive negotiation process, the company has secured the joint R&D project for a \"Feline Quadrivalent Inactivated Vaccine (against feline panleukopenia virus, calicivirus, herpesvirus, and mycoplasma) and a Feline Mycoplasma Inactivated Vaccine.\" Under the agreement, the company will pay Huazhong Agricultural University RMB 1 million for the research initiative.</p>\n<p>This partnership is expected to expand the company's product pipeline and improve its competitive position in the market. However, as the project involves early-stage R&D, there are uncertainties regarding successful product development, time to market, and post-launch commercial performance. The impact of the project on the company's current and future financial results cannot be reliably estimated at this stage.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"688526","symbol_name":"科前生物","start_time":0,"source_url":"","article_id":"1176014928","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1176014928","pubTimestamp":1774343896,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Wuhan Keqian Biology Co.,Ltd. (688526.SH) has announced plans to sign a joint research and development agreement with Huazhong Agricultural University. The collaboration aims to enhance the company's...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688526":"科前生物","BK0239":"医药制造"},"translate_title":"武汉科前生物将与华中农业大学签订联合研发协议","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688526":1},"content_text":"Wuhan Keqian Biology Co.,Ltd. (688526.SH) has announced plans to sign a joint research and development agreement with Huazhong Agricultural University. The collaboration aims to enhance the company's market competitiveness and accelerate its growth within the biological products sector, thereby strengthening its brand influence and core capabilities.\nFollowing a competitive negotiation process, the company has secured the joint R&D project for a \"Feline Quadrivalent Inactivated Vaccine (against feline panleukopenia virus, calicivirus, herpesvirus, and mycoplasma) and a Feline Mycoplasma Inactivated Vaccine.\" Under the agreement, the company will pay Huazhong Agricultural University RMB 1 million for the research initiative.\nThis partnership is expected to expand the company's product pipeline and improve its competitive position in the market. However, as the project involves early-stage R&D, there are uncertainties regarding successful product development, time to market, and post-launch commercial performance. The impact of the project on the company's current and future financial results cannot be reliably estimated at this stage.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1176014928","isCrawlerRequest":true}